Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-10107
Carteni, G; Manegold, C; Martin Garcia, G; Siena, S; Zielinski, C C; Amadori, D; Liu, Y; Blatter, J; Visseren-Grul, C; Stahel, R (2009). Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer, 64(2):211-218.
- Registered users only
AIM: Peritoneal mesothelioma (PM) has rarely been studied. The Expanded Access Program (EAP) provided access to 109 patients with PM.
METHODS: This was a nonrandomized, open-label study conducted in chemo-naïve or previously treated patients with PM not amenable to curative surgery. Patients received pemetrexed (PEM) 500mg/m(2) alone or with cisplatin (CIS) 75mg/m(2) or carboplatin (CARBO) AUC 5 every 21 days, supplemented with standard vitamin B(12), folate, and dexamethasone.
RESULTS: Response rates (95% CI) for PEM, PEM/CIS, and PEM/CARBO were 12.5% (3.5, 29.0), 20.0% (7.7, 38.6), and 24.1% (10.3, 43.5), respectively. Median survival for PEM was 10.3 months. One-year survival rates for PEM/CIS and PEM were 57.4% (95% CI: 10.3, 100) and 41.5% (95% CI: 4.6, 78.4), respectively, and were not available for PEM/CARBO. Anemia was the most common serious adverse event (6.4%). Neutropenia (34.6%) was the most frequent CTC grade 3 or 4 toxicity reported.
CONCLUDING STATEMENT: PEM with or without a platinum agent was both active and well tolerated in patients with peritoneal mesothelioma.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology|
|DDC:||610 Medicine & health|
|Deposited On:||13 Jan 2009 11:27|
|Last Modified:||28 Nov 2013 01:02|
|Citations:||Web of Science®. Times Cited: 19|
Scopus®. Citation Count: 22
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page